Home > Resource Library >
Discovery / Non-clinical
Is there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?
The Pharmaceutical Marketing Group publishes Jonathan Trethowan’s opinion on how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit
Posted:
ReadIs there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?
Jonathan Trethowan looks at how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit
Posted:
ReadBrexit Uncertainty - impact on medicines supply
PharmaLex Vice President Regulatory and Scientific Policy, Jonathan Trethowan looks at what impact Brexit might have on medicines supply across the EU
Posted:
ReadThe Pink Sheet - Big Data: Moving From Artificial Trials To A Smarter Regulatory Process
PharmaLex’s Bruno Boulanger discusses the impact big data will have on how the pharmaceutical industry gathers and delivers data in the future. *subscription required*
Posted:
ReadThe 5 things you want to know about Artificial Intelligence
PharmaLex CEO, Tilo Netzer explains the five things you should know about Artificial Intelligence
Posted:
ReadClinical Development
Drug Development Decisions
Zeb Younes & Zaklina Buljovcic will give you insightful information about new approaches to Drug Development. This article is taken from the European Biopharmaceutical Review October 2019, pages 58-64. © Samedan Ltd.
Posted:
ReadThe FDA is shifting focus to both ends of the product development spectrum
PharmaLex’s Andrew S. Verderame looks at how the FDA are introducing new measures to process and approve more complex novel and generic therapies – p52-53
Posted:
ReadEPR - Are you giving regulatory intelligence the platform it deserves?
PharmaLex’s Jürgen Hönig and Rob Williams discuss the key elements of developing a successful knowledge-management plan – p12
Posted:
ReadIs there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?
The Pharmaceutical Marketing Group publishes Jonathan Trethowan’s opinion on how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit
Posted:
ReadSpot the Difference
Torben Thers Nørgaard looks at Scandinavia and how the countries have very different rules and regulations when it comes to doing business: http://www.samedanltd.com/magazine/12.
Posted:
ReadIs there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?
Jonathan Trethowan looks at how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit
Posted:
ReadRegulatory intelligence – from knowledge to added value
Dr. Jürgen Hönig and Rob Williams look into the benefits of having the right information.
Posted:
ReadBrexit Uncertainty - impact on medicines supply
PharmaLex Vice President Regulatory and Scientific Policy, Jonathan Trethowan looks at what impact Brexit might have on medicines supply across the EU
Posted:
ReadArtificial Intelligence in drug development: What are current use cases? - Part 2: Pharmacovigilance
PharmaLex CEO, Tilo Netzer looks at the opportunities for AI in drug development, examining the use cases in relation to pharmacovigilance
Posted:
ReadArtificial Intelligence in drug development: What are current use cases? - Part 1: Regulatory Affairs
PharmaLex CEO, Tilo Netzer looks at the opportunities for AI in drug development, examining the use cases in relation to regulatory affairs
Posted:
ReadThe Pink Sheet - Big Data: Moving From Artificial Trials To A Smarter Regulatory Process
PharmaLex’s Bruno Boulanger discusses the impact big data will have on how the pharmaceutical industry gathers and delivers data in the future. *subscription required*
Posted:
ReadThe 5 things you want to know about Artificial Intelligence
PharmaLex CEO, Tilo Netzer explains the five things you should know about Artificial Intelligence
Posted:
ReadPost-approval / Maintenance
Complying Confidently? Learning Lessons from Nitrosamine Impurities
PharmaLex.pert Diego Martinez discusses why industry must never become complacent about the safety of drug products and should seek to continually perform surveillance even if the drug is well-established.
Posted:
ReadIs there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?
The Pharmaceutical Marketing Group publishes Jonathan Trethowan’s opinion on how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit
Posted:
ReadSpot the Difference
Torben Thers Nørgaard looks at Scandinavia and how the countries have very different rules and regulations when it comes to doing business: http://www.samedanltd.com/magazine/12.
Posted:
ReadIs there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?
Jonathan Trethowan looks at how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit
Posted:
ReadEMA simplifies the process for internal transfer of MAs
PharmaLex Vice President Regulatory and Scientific Policy, Jonathan Trethowan discusses how the EMA’s simplified process for internal transfer of marketing authorizations may help some Brexit Impacted MAHs.
Posted:
ReadBrexit Uncertainty - impact on medicines supply
PharmaLex Vice President Regulatory and Scientific Policy, Jonathan Trethowan looks at what impact Brexit might have on medicines supply across the EU
Posted:
ReadThe 5 things you want to know about Artificial Intelligence
PharmaLex CEO, Tilo Netzer explains the five things you should know about Artificial Intelligence
Posted:
Read